Unlocking the epigenetic code: new insights into triple-negative breast cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2/neu receptors, limiting treatment options.
• Epigenetic modifications, including DNA methylation, histone modifications, and microRNA regulation, are crucial in TNBC development.
• Novel therapeutic strategies are needed to address the challenges posed by TNBC.

Purpose of the Study:

• To review the therapeutic potential of epigenetic interventions in TNBC.
• To focus on DNA methylation, histone modifications, and miRNA-based therapies for TNBC.
• To explore a multifaceted approach combining epigenetic therapies for improved outcomes.

Main Methods:

• Review of current literature on epigenetic modifications in TNBC.
• Examination of DNA methylation inhibitors for tumor suppressor gene reactivation.
• Analysis of histone deacetylase inhibitors (HDACi) for gene expression regulation.
• Discussion of miRNA mimics and inhibitors for modulating oncogenic and tumor-suppressive miRNAs.

Main Results:

• DNA methylation inhibitors can reactivate silenced tumor suppressor genes in TNBC.
• HDAC inhibitors show promise in suppressing tumor growth by reversing aberrant histone deacetylation.
• miRNA-based therapies can modulate oncogenes and tumor suppressors, inhibiting cancer progression.
• Synergistic application of these epigenetic therapies presents a viable strategy.

Conclusions:

• Epigenetic interventions targeting DNA methylation, histone modifications, and miRNAs offer significant therapeutic potential for TNBC.
• A combination of DNA methylation inhibitors, HDACi, and miRNA-based therapies can provide a multifaceted approach.
• This integrated strategy holds promise for personalized treatment and improved clinical outcomes in TNBC patients.